These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 10706628)
1. Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells. Dembic Z; Schenck K; Bogen B Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2697-702. PubMed ID: 10706628 [TBL] [Abstract][Full Text] [Related]
2. A mouse model for immunotherapy of myeloma. Bogen B Hematol J; 2002; 3(5):224-9. PubMed ID: 12391539 [TBL] [Abstract][Full Text] [Related]
3. Clonal deletion of thymocytes as a tumor escape mechanism. Lauritzsen GF; Hofgaard PO; Schenck K; Bogen B Int J Cancer; 1998 Oct; 78(2):216-22. PubMed ID: 9754655 [TBL] [Abstract][Full Text] [Related]
4. Anti-class II antibodies, but not cytotoxic T-lymphocyte antigen 4-immunoglobulin hybrid molecules, prevent rejection of major histocompatibility complex class II-negative myeloma in T-cell receptor-transgenic mice. Dembic Z; Hofgaard PO; Omholt H; Bogen B Scand J Immunol; 2004; 60(1-2):143-52. PubMed ID: 15238083 [TBL] [Abstract][Full Text] [Related]
5. Immunotherapy in multiple myeloma: Id-specific strategies suggested by studies in animal models. Corthay A; Lundin KU; Munthe LA; Frøyland M; Gedde-Dahl T; Dembic Z; Bogen B Cancer Immunol Immunother; 2004 Sep; 53(9):759-69. PubMed ID: 15088126 [TBL] [Abstract][Full Text] [Related]
6. The role of idiotype-specific, CD4+ T cells in tumor resistance against major histocompatibility complex class II molecule negative plasmacytoma cells. Lauritzsen GF; Bogen B Cell Immunol; 1993 Apr; 148(1):177-88. PubMed ID: 8098665 [TBL] [Abstract][Full Text] [Related]
7. Secretion of tumor-specific antigen by myeloma cells is required for cancer immunosurveillance by CD4+ T cells. Corthay A; Lundin KU; Lorvik KB; Hofgaard PO; Bogen B Cancer Res; 2009 Jul; 69(14):5901-7. PubMed ID: 19567679 [TBL] [Abstract][Full Text] [Related]
8. In vitro hematopoiesis produces a distinct class of immature dendritic cells from spleen progenitors with limited T cell stimulation capacity. Quah B; Ni K; O'Neill HC Int Immunol; 2004 Apr; 16(4):567-77. PubMed ID: 15039387 [TBL] [Abstract][Full Text] [Related]
9. Neoantigen vaccine-induced CD4 T cells confer protective immunity in a mouse model of multiple myeloma through activation of CD8 T cells against non-vaccine, tumor-associated antigens. Bekri S; Rodney-Sandy R; Gruenstein D; Mei A; Bogen B; Castle J; Levey D; Cho HJ J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35190376 [TBL] [Abstract][Full Text] [Related]
10. Encounter with antigen-specific primed CD4 T cells promotes MHC class II degradation in dendritic cells. Furuta K; Ishido S; Roche PA Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19380-5. PubMed ID: 23129633 [TBL] [Abstract][Full Text] [Related]
11. Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences. Fredriksen AB; Bogen B Blood; 2007 Sep; 110(6):1797-805. PubMed ID: 17540847 [TBL] [Abstract][Full Text] [Related]
12. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12. Homma S; Komita H; Sagawa Y; Ohno T; Toda G Immunology; 2005 Aug; 115(4):451-61. PubMed ID: 16011514 [TBL] [Abstract][Full Text] [Related]
13. Efficient delivery of T cell epitopes to APC by use of MHC class II-specific Troybodies. Lunde E; Western KH; Rasmussen IB; Sandlie I; Bogen B J Immunol; 2002 Mar; 168(5):2154-62. PubMed ID: 11859101 [TBL] [Abstract][Full Text] [Related]
14. Peptide-specific intercellular transfer of MHC class II to CD4+ T cells directly from the immunological synapse upon cellular dissociation. Wetzel SA; McKeithan TW; Parker DC J Immunol; 2005 Jan; 174(1):80-9. PubMed ID: 15611230 [TBL] [Abstract][Full Text] [Related]
15. Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells. Wen YJ; Barlogie B; Yi Q Blood; 2001 Mar; 97(6):1750-5. PubMed ID: 11238117 [TBL] [Abstract][Full Text] [Related]
16. Dendritic cells, but not macrophages or B cells, activate major histocompatibility complex class II-restricted CD4+ T cells upon immune-complex uptake in vivo. de Jong JM; Schuurhuis DH; Ioan-Facsinay A; Welling MM; Camps MG; van der Voort EI; Huizinga TW; Ossendorp F; Verbeek JS; Toes RE Immunology; 2006 Dec; 119(4):499-506. PubMed ID: 16995881 [TBL] [Abstract][Full Text] [Related]
17. CD11c+ antigen presenting cells from the alveolar space, lung parenchyma and spleen differ in their phenotype and capabilities to activate naïve and antigen-primed T cells. Kugathasan K; Roediger EK; Small CL; McCormick S; Yang P; Xing Z BMC Immunol; 2008 Aug; 9():48. PubMed ID: 18700962 [TBL] [Abstract][Full Text] [Related]
18. Stroma-dependent development of two dendritic-like cell types with distinct antigen presenting capability. Periasamy P; O'Neill HC Exp Hematol; 2013 Mar; 41(3):281-92. PubMed ID: 23178375 [TBL] [Abstract][Full Text] [Related]
19. Is secretion of tumour-specific antigen important for cancer eradication by CD4(+) T cells?--Implications for cancer immunotherapy by adoptive T cell transfer. Corthay A; Lorvik KB; Bogen B Scand J Immunol; 2011 Jun; 73(6):527-30. PubMed ID: 21388431 [TBL] [Abstract][Full Text] [Related]
20. Tumor-specific CD4+ T cells eradicate myeloma cells genetically deficient in MHC class II display. Tveita A; Fauskanger M; Bogen B; Haabeth OA Oncotarget; 2016 Oct; 7(41):67175-67182. PubMed ID: 27626487 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]